Reason for request
Inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals in the ‘Central neuropathic pain in adults’ indication extension.
Clinical Benefit
| Substantial |
The actual benefit of LYRICA in the treatment of central neuropathic pain in adults is substantial. |
Clinical Added Value
| no clinical added value |
Lyrica does not provide any improvement in actual benefit (IAB level V) over the usual management of central neuropathic pain in adults. |
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
Q13hWGNemEERAhBR
